Search - Inserm - Institut national de la santé et de la recherche médicale Access content directly

Filter your results

15 Results
Author: personID (integer) : 761084
Image document

Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France Trial

Julien Taieb , Valérie Taly , Julie Henriques , Camille Bourreau , Laurent Mineur , et al.
Clinical Cancer Research, 2021, 27 (20), pp.5638-5646. ⟨10.1158/1078-0432.CCR-21-0271⟩
Journal articles inserm-03405591v1
Image document

Decision for adjuvant treatment in stage II colon cancer based on circulating tumor DNA:The CIRCULATE-PRODIGE 70 trial

Julien Taïeb , Léonor Benhaim , Pierre Laurent Puig , Karine Le Malicot , Jean François Emile , et al.
Digestive and Liver Disease, 2020, 52 (7), pp.730-733. ⟨10.1016/j.dld.2020.04.010⟩
Journal articles inserm-02992943v1
Image document

Association of COVID-19 Lockdown With the Tumor Burden in Patients With Newly Diagnosed Metastatic Colorectal Cancer

Alain Thierry , Brice Pastor , Ekaterina Pisareva , Francois Ghiringhelli , Olivier Bouché , et al.
JAMA Network Open, 2021, 4 (9), pp.e2124483. ⟨10.1001/jamanetworkopen.2021.24483⟩
Journal articles hal-03649599v1
Image document

STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer

Benoist Chibaudel , Franck Bonnetain , Christophe Tournigand , Marine Hug de Larauze , Armand de Gramont , et al.
BMC Cancer, 2015, 15, pp.496. ⟨10.1186/s12885-015-1503-7⟩
Journal articles hal-01211687v1
Image document

A comprehensive overview of promising biomarkers in stage II colorectal cancer

Pauline Parent , Romain Cohen , Elie Rassy , Magali Svrcek , Julien Taieb , et al.
Cancer Treatment Reviews, 2020, 88, pp.102059 -. ⟨10.1016/j.ctrv.2020.102059⟩
Journal articles hal-03492180v1
Image document

Fusions NTRK : une nouvelle piste dans les cancers digestifs ?

Kaïssa Ouali , Anna Pellat , Romain Cohen , Magali Svrcek , Frédérique Penault-Llorca , et al.
Bulletin du Cancer, 2020, 107 (4), pp.447-457. ⟨10.1016/j.bulcan.2019.11.014⟩
Journal articles hal-02882231v1

Concomitant administration of weekly oxaliplatin, fluorouracil continuous infusion, and radiotherapy after 2 months of gemcitabine and oxaliplatin induction in patients with locally advanced pancreatic cancer: a Groupe Coordinateur Multidisciplinaire en Oncologie phase II study.

Laurence Moureau-Zabotto , Jean-Marc Phélip , Pauline Afchain , Laurent Mineur , Thierry André , et al.
Journal of Clinical Oncology, 2008, 26 (7), pp.1080-5. ⟨10.1200/JCO.2007.12.8223⟩
Journal articles inserm-00376398v1
Image document

The immune microenvironment in patients with mismatch‐repair‐proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study

Marine Jary , Wen‐wei Liu , Dongyao Yan , Isaac Bai , Andrea Muranyi , et al.
Molecular Oncology, 2021, ⟨10.1002/1878-0261.13173⟩
Journal articles hal-03510003v1
Image document

Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial

Stefano Kim , Bruno Buecher , Thierry André , Marine Jary , François-Clément Bidard , et al.
BMC Cancer, 2020, 20 (1), pp.352. ⟨10.1186/s12885-020-06841-1⟩
Journal articles hal-03130294v1
Image document

Understanding the Prognostic Value of Primary Tumor Location and KRAS in Metastatic Colorectal Cancer: A Post Hoc Analysis of the OPTIMOX3 DREAM Phase III Study

Benoist Chibaudel , Thierry André , Christophe Tournigand , Christophe Louvet , Magdalena Benetkiewicz , et al.
Clinical Colorectal Cancer, 2020, 19, pp.200 - 208.e1. ⟨10.1016/j.clcc.2020.02.012⟩
Journal articles hal-03492386v1
Image document

Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency

R. Cohen , O. Buhard , P. Cervera , Elisabeth Hain , S. Dumont , et al.
European Journal of Cancer, 2017, 86, pp.266-274. ⟨10.1016/j.ejca.2017.09.022⟩
Journal articles hal-01628456v1

Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status

Romain Cohen , Elisabeth Hain , Olivier Buhard , Agathe Guilloux , Armelle Bardier , et al.
JAMA oncology, 2019, 5 (4), pp.551-555. ⟨10.1001/jamaoncol.2018.4942⟩
Journal articles hal-02419371v1
Image document

Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer

Raphael Colle , Anna Radzik , Romain Cohen , Anna Pellat , Daniel Lopez-Tabada , et al.
European Journal of Cancer, 2021, 144, pp.9 - 16. ⟨10.1016/j.ejca.2020.11.009⟩
Journal articles hal-03492747v1

Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies.

Florence Huguet , Thierry André , Pascal Hammel , Pascal Artru , Jacques Balosso , et al.
Journal of Clinical Oncology, 2007, 25 (3), pp.326-31. ⟨10.1200/JCO.2006.07.5663⟩
Journal articles inserm-00383864v1
Image document

PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer

Benoist Chibaudel , Frédérique Maindrault-Goebel , Jean-Baptiste Bachet , Christophe Louvet , Ahmed Khalil , et al.
Cancer Medicine, 2016, 5 (4), pp.676-683. ⟨10.1002/cam4.635⟩
Journal articles hal-01312777v1